Updated:
ImpediMed Limited
ImpediMed’s bioimpedance spectroscopy (BIS) devices accurately and noninvasively aid for early detection, assessment, and intervention in chronic diseases.
ImpediMed Limited
ImpediMed’s bioimpedance spectroscopy (BIS) devices accurately and noninvasively aid for early detection, assessment, and intervention in chronic diseases.
General information
Firm type
Asset Manager
Year founded
1987
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Principals
Erik Anderson
Chief Executive Officer
Erik Anderson
Board of Directors
Sector focus
Frequently asked questions
Who leads ImpediMed?
Erik Anderson was appointed CEO in 2026; he also serves on the board. Previous leaders are not publicly detailed on the current website (per firm website, 2026).
What is ImpediMed's core technology?
ImpediMed's SOZO Digital Health Platform uses bioimpedance spectroscopy (BIS) to noninvasively measure fluid status and tissue composition. It is FDA-cleared and performs a single scan at 256 frequencies to separate intra- and extracellular fluid (per firm website).
What clinical conditions does ImpediMed address?
The company focuses on four areas: cancer survivorship (lymphedema risk up to 58% in some populations), wellness and longevity, medical weight management (GLP-1 therapy can reduce muscle mass by up to 20%), and heart failure (affecting ~64 million people globally) (per firm website, citing published references).
Is ImpediMed a public or private company?
ImpediMed is listed on the Australian Stock Exchange (ASX) with operations in the United States, Europe, and Australia (per firm website).
Does ImpediMed disclose its financials or AUM?
No. ImpediMed is an operating medical technology company, not an investment vehicle, and does not publicly disclose AUM or investment deployment figures.
What are the key products of ImpediMed?
The SOZO Digital Health Platform includes three applications: L-Dex for lymphedema detection, BodyComp for fluid and tissue composition tracking, and HF-Dex for heart failure fluid management. All are FDA-cleared (per firm website).
Where does ImpediMed operate geographically?
The company is headquartered in Carlsbad, California, with operations in the United States, Europe, and Australia (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: